Skip to main content

Advertisement

SpringerLink
Log in

Evaluation of the effect of compression therapy using surgical gloves on nanoparticle albumin-bound paclitaxel-induced peripheral neuropathy: a phase II multicenter study by the Kamigata Breast Cancer Study Group

  • Clinical Trial
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Purpose

To investigate the efficacy of using surgical glove (SG) compression therapy to prevent nanoparticle albumin-bound paclitaxel (nab-PTX)-induced peripheral neuropathy.

Patients and methods

Patients with primary and recurrent breast cancer who received 260 mg/m2 of nab-PTX were eligible for this case-control study. Patients wore two SGs of the same size, i.e., one size smaller than the size that fit their dominant hand, for only 90 min. They did not wear two SGs on the non-dominant hand, which served as the control hand. Peripheral neuropathy was evaluated at each treatment cycle using common terminology criteria for adverse events (CTCAE) version 4.0 and the Patient Neurotoxicity Questionnaire. The temperature of each fingertip of the compression SG-protected hand and control hand was measured using thermography.

Results

Between August 2013 and January 2016, 43 patients were enrolled and 42 were evaluated. The occurrence rates of CTCAE grade 2 or higher sensory and motor peripheral neuropathies were significantly lower for SG-protected hands than for control hands (sensory neuropathy 21.4 vs. 76.1 %; motor neuropathy 26.2 vs. 57.1 %). No patients withdrew from this study because they could not tolerate the compression from the SGs. SG compression therapy significantly decreased the temperature of each fingertip by 1.6–2.2 °C as compared with the temperature before chemotherapy (p < 0.0001).

Conclusions

SG compression therapy is effective for reducing nab-PTX-induced peripheral neuropathy. The nab-PTX exposure to the peripheral nerve may be decreased because the SG decreases microvascular flow to the fingertip.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Blumenthal DT (2009) Assessment of neuropathic pain in cancer patients. Curr Pain Headache Rep 13:282–287

    Article  PubMed  Google Scholar 

  2. Hausheer FH, Schilsky RL, Bain S et al (2006) Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol 33:15–49

    Article  CAS  PubMed  Google Scholar 

  3. Paice JA (2009) Clinical challenges: chemotherapy-induced peripheral neuropathy. Semin Oncol Nurs 25(suppl 1):S8–S19

    Article  PubMed  Google Scholar 

  4. Ewertz M, Qvortrup C, Eckhoff L (2015) Chemotherapy-induced peripheral neuropathy in patients treated with taxanes and platinum derivative. Acta Oncol 54:587–591

    Article  CAS  PubMed  Google Scholar 

  5. Yamamoto Y, Kawano I, Iwase H (2011) Nab-paclitaxel for the treatment of breast cancer: efficacy, safety, and approval. Onco Targets Ther 4:123–136

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Yamada K, Yamamoto N, Yamada Y et al (2010) Phase I and pharmacokinetic study of ABI-007, albumin-bound paclitaxel, administered every 3 weeks in Japanese patients with solid tumors. Jpn J Clin Oncol 40:404–411

    Article  PubMed  PubMed Central  Google Scholar 

  7. Rivera E, Cianfrocca M (2015) Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer. Cancer Chemother Pharmacol 75:659–670

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Gradishar WJ, Tjulandin S, Davidson N et al (2005) Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23:7794–7803

    Article  CAS  PubMed  Google Scholar 

  9. Gradishar WJ, Krasnojon D, Cheporov S et al (2012) Phase II trial of nab-paclitaxel compared with docetaxel as first-line chemotherapy in patients with metastatic breast cancer: final overall survival (OS) analysis of a randomized phase 2 trial. Clin Breast Cancer 12:313–321

    Article  CAS  PubMed  Google Scholar 

  10. Hershman DL, Lacchetti C, Dworkin RH et al (2014) Prevention and management of chemotherapy- induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 32:1941–1967

    Article  CAS  PubMed  Google Scholar 

  11. Scotté F, Tourani JM, Banu E et al (2005) Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand. J Clin Oncol 23:4424–4429

    Article  PubMed  Google Scholar 

  12. Eckhoff L, Knoop AS, Jensen MB et al (2013) Risk of docetaxel-induced peripheral neuropathy among 1725 Danish patients with early stage breast cancer. Breast Cancer Res Treat 142:109–118

    Article  CAS  PubMed  Google Scholar 

  13. Ohno T, Mine T, Yoshioka H et al (2014) Management of peripheral neuropathy induced by nab-paclitaxel treatment for breast cancer. Anticancer Res 34:4213–4216

    CAS  PubMed  Google Scholar 

  14. Nakamura S, Iwata H, Funato Y, Ito K, Ito Y (2015) Results of a drug use investigation of nanoparticle albumin-bound Paclitaxel for breast cancer. Gan To Kagaku Ryoho 42(4):447–455

    PubMed  Google Scholar 

  15. Pachman DR, Barton DL, Watson JC et al (2011) Chemotherapy-induced peripheral neuropathy: prevention and treatment. Clin Pharmacol Ther 90:377–387

    Article  CAS  PubMed  Google Scholar 

  16. Swain SM, Arezzo JC (2008) Neuropathy associated with microtubule inhibitors: diagnosis, incidence, and management. Clin Adv Hematol Oncol 6:455–467

    PubMed  Google Scholar 

  17. Lee JJ, Swain SM (2006) Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol 24:1633–1642

    Article  CAS  PubMed  Google Scholar 

  18. Smith EM, Pang H, Cirrincione C et al (2013) Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 309:1359–1367

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Hirayama Y, Ishitani K, Sato Y et al (2015) Effect of duloxetine in Japanese patients with chemotherapy-induced peripheral neuropathy: a pilot randomized trial. Int J Clin Oncol 20:866–871

    Article  CAS  PubMed  Google Scholar 

  20. Shigematsu H, Kadoya T, Masumoto N et al (2015) The efficacy and safety of preoperative chemotherapy with triweekly abraxane and cyclophosphamide followed by 5-fluorouracil, epirubicin, and cyclophosphamide therapy for resectable breast cancer: a multicenter clinical trial. Clin Breast Cancer 15(2):110–116

    Article  CAS  PubMed  Google Scholar 

  21. McArthur HL, Rugo H, Nulsen B et al (2011) A Feasibility study of Bevacizumab plus dose-dense doxorubicin–cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer. Clin Cancer Res 17(10):3398–3407

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Robert N, Krekow L, Stokoe C et al (2011) Adjuvant dose-dense doxorubicin plus cyclophosphamide followed by dose-dense nab-paclitaxel is safe in women with early-stage breast cancer: a pilot study. Breast Cancer Res Treat 125(1):115–120

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Prof. Toshiro Katayama of the Faculty of Health Sciences, Department of Medical Engineering, Himeji Dokkyo University (Himeji, Hyogo, Japan) for critically reviewing the statistical analysis of our study.

Author information

Authors and Affiliations

  1. Department of Breast Surgery, Osaka Red Cross Hospital, 5-30 Fudegasaki-cho, Tennoji-ku, Osaka, 543-8555, Japan

    Shigeru Tsuyuki, Noriko Senda & Yookija Kanng

  2. Department of Breast Surgery, Graduate School of Medicine, Kyoto University, 54 Kawaharacho Shogoin, Sakyo-ku, Kyoto, Japan

    Ayane Yamaguchi

  3. Department of Breast Surgery, Japanese Red Cross Society Wakayama Medical Center, 4-20, Komatsubara, Wakayama, Japan

    Hiroshi Yoshibayashi

  4. Department of Breast Surgery, Kobe City Medical Center West Hospital, 2-4, Ichiban-cho, Nagata-ku, Kobe, Japan

    Yuichiro Kikawa

  5. Department of Breast Surgery, Kobe City Medical Center Central Hospital, 2-1-1, Minatojima, Minamimachi, Chuo-ku, Kobe, Japan

    Yuichiro Kikawa & Hironori Kato

  6. Department of Integrated Oncology, Institute of Biomedical Research and Innovation Hospital, 2-2, Minatojima Minamimachi, Chuo-ku, Kobe, Japan

    Nobuyuki Katakami

  7. Hashimoto Clinic, 1-7-2, Sumimoto Honnmati, Nada-ku, Kobe, Japan

    Takashi Hashimoto

  8. Department of Breast Surgery, Nishi-Kobe Medical Center, 5-7-1, Kojidai, Nishi-ku, Kobe, Japan

    Toshitaka Okuno

  9. Department of Breast Surgery, Tazuke Kofukai Medical Research Institute, Kitano Hospital, 2-4-20, Ohgimachi, Kita-ku, Osaka, Japan

    Akira Yamauchi & Takashi Inamoto

  10. Department of Nursing Science, Tenri Health Care University, 80-1, Besho-cho, Tenri-city, Nara, Japan

    Takashi Inamoto

Authors
  1. Shigeru Tsuyuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Noriko Senda
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yookija Kanng
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ayane Yamaguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hiroshi Yoshibayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yuichiro Kikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Nobuyuki Katakami
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hironori Kato
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Takashi Hashimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Toshitaka Okuno
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Akira Yamauchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Takashi Inamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shigeru Tsuyuki.

Ethics declarations

Conflict of interest

Nobuyuki Katakami received research funds from AstraZeneca, Eisai, Ono Pharmaceutical, Kyowa Hakko Kirin, Shionogi Pharma, Daiichi Sankyo, Taiho Pharmaceutical, Chugai Pharma, Lilly, Beohringer Ingelheim, Merck Serono, MSD, Maruishi Pharma, Astellas Pharma, Bristol-Myers Squibb, and Amgen. All remaining authors have no conflicts of interest to declare.

Ethical approval

All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tsuyuki, S., Senda, N., Kanng, Y. et al. Evaluation of the effect of compression therapy using surgical gloves on nanoparticle albumin-bound paclitaxel-induced peripheral neuropathy: a phase II multicenter study by the Kamigata Breast Cancer Study Group. Breast Cancer Res Treat 160, 61–67 (2016). https://doi.org/10.1007/s10549-016-3977-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-016-3977-7

Keywords

Search

Navigation